NC-PERCONA
23.5.2023 15:01:36 CEST | Business Wire | Press release
Percona, a leader in enterprise-grade open source database software, support, and services, today announced the initial findings of its State of Open Source Database Survey report for 2023 during its annual Percona Live conference. According to the survey of nearly 300 database professionals working in companies ranging in size from small-to-medium-sized business to large enterprise, the database market is currently in a period of stasis around database deployments and changes, most likely due to economic uncertainty and post-COVID-19 recovery. The research indicates that most organizations are not planning to make significant alterations to their database strategies over the course of the next three years.
Alongside this broader revelation, the study sheds light on a number of database operations concerns for organizations, including challenges around developer agility, and significant factors driving the choice between deploying open source or proprietary databases.
Findings in the 2023 State of Open Source Database Survey include:
-
More respondents indicate their organizations are doing well with a host of database operations metrics than they are with meeting developer needs:
- More than 70 percent of respondents say they are doing somewhat or extremely well with database reliability, performance, security, privacy, scalability and backup reliability and integrity.
- Conversely, meeting the needs of developers placed last on the list of 14 operational metrics collected, with only 55 percent of respondents saying they are doing well in developer agility.
-
Comparing large enterprises and small-to-medium businesses, the research shows that bigger companies tend to have more tools and automation deployed to help their teams:
- Large enterprises are much more likely to use database monitoring and management solutions, with 93 percent of organizations having such tools in place. Conversely, only 57 percent of small businesses have database monitoring and management solutions deployed.
- Small companies are much more likely to use on-premises and cloud services to host their databases (49 percent) compared to 26 percent of large enterprises. Large enterprises are also much more likely to use DBaaS offerings (32 percent of deployments).
“Our report indicates that database deployment strategies are expected to remain static for the next few years, with levels of usage remaining consistent across all categories of relational and non-relational databases,” said Joe Brockmeier, Head of Community at Percona. “We’re seeing caution around making significant changes to deployments following the large-scale digital transformation undertaken during the pandemic and the uncertain economic climate the world is facing in 2023. Teams want to improve how they manage, monitor and run those deployments rather than implementing more changes.”
Further findings include:
- When asked about what drove their choice to use open source databases, respondents most often cited cost reductions (83 percent rated as somewhat or extremely significant) and developer choice (81 percent), followed by faster deployment (75 percent) and then security and more control (73 percent each).
- For respondents that implemented proprietary databases, the findings are very different – the biggest factors are greater stability (68 percent), more security (63 percent) and regulatory compliance (61).
- Developer choice was not in the top ten reasons to deploy proprietary databases, pointing to a much larger preference for open source solutions for the developer community.
-
The majority of respondents say their organizations rely on both relational and non-relational databases – 99 percent of respondents run at least one relational database, and 86 percent run at least one non-relational database.
- MySQL is the most popular relational database, followed by PostgreSQL and Oracle Server at 57, 48 and 47 percent respectively.
- MongoDB is the most commonly deployed non-relational database, followed by Couchbase and Redis.
“Developers prefer open source software where they have choice and autonomy over how they can architect and build their applications. The flexibility and performance benefits aside, open source also helps companies save on costs compared to running proprietary databases, which can’t be ignored in today’s economy. However, companies can still improve how they run and manage those installations, and that is where Percona can really help,” said Ann Schlemmer, CEO at Percona.
Speakers at this year’s Percona Live will discuss these and other findings from the 2023 survey. Percona Live is sponsored by a range of companies in the data and database markets, including Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver.
If you would like to be notified when the full report from this survey is made available, please send an email with the request to: databasesurvey@percona.com
About Percona
Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries, creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.
Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.
Databases run better with Percona.
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005396/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
